|  | 
| Tumor pathological and immunological changes in HER2+ metastatic breast cancer (MBC) following trastuzumab combined with expanded and activated autologous natural killer (NK) cell infusion. | 
|  | 
|  | 
| No Relationships to Disclose | 
|  | 
|  | 
| Patents, Royalties, Other Intellectual Property - Nkarta | 
|  | 
|  | 
| No Relationships to Disclose | 
|  | 
|  | 
| Honoraria - Novartis; Pfizer | 
| Research Funding - Otsuka | 
| Travel, Accommodations, Expenses - Eisai; Pfizer | 
|  | 
|  | 
| Consulting or Advisory Role - Pfizer; Pfizer | 
| Travel, Accommodations, Expenses - AstraZeneca; Novartis | 
|  | 
|  | 
| No Relationships to Disclose | 
|  | 
|  | 
| No Relationships to Disclose | 
|  | 
|  | 
| No Relationships to Disclose | 
|  | 
|  | 
| Consulting or Advisory Role - Bayer; Otsuka | 
| Research Funding - Bayer; Genentech/Roche; Kyowa Hakko Kirin | 
|  | 
|  | 
| Stock and Other Ownership Interests  - Medisix Therapeutics; Nkarta; Unum Therapeutics | 
| Consulting or Advisory Role - Lion TCR; Medisix Therapeutics | 
| Patents, Royalties, Other Intellectual Property - Juno Therapeutics; Medisix therapeutics; Nkarta; Unum Therapeutics | 
| Travel, Accommodations, Expenses - Celgene; GlaxoSmithKline | 
|  | 
|  | 
| No Relationships to Disclose |